ANTH Insider Trading Activity and SEC Form 4 Filings
ANTH insider trading summary
No open-market insider purchases or sales of Anthera Pharmaceuticals Inc (ANTH) have been reported on SEC Form 4 in the past 12 months.
Latest ANTH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 20, 2017 | John Craig Thompson | President & CEO | Buy | $11K (8,550 @ $1.32) |
| Sep 7, 2017 | Paul F Truex | Insider | Buy | $7K (5,000 @ $1.34) |
| Nov 13, 2015 | Colin Hislop | Chief Medical Officer | Sell | $66K (12,500 @ $5.31) |
| Nov 11, 2015 | Colin Hislop | Chief Medical Officer | Sell | $27K (5,000 @ $5.38) |
| Oct 12, 2015 | Debra Odink | Chief Technology Officer | Sell | $7K (1,205 @ $6.15) |
| Jun 24, 2013 | David E. Thompson | Insider | Buy | $53K (100,000 @ $0.53) |
| May 31, 2013 | Bogdan Dziurzynski | Insider | Buy | $6K (10,000 @ $0.59) |
| Jan 30, 2013 | OrbiMed Capital GP IV LLC | Director | Buy | $3.8M (5,700,000 @ $0.66) |
| Jan 30, 2013 | Orbimed Advisors LLC | Director | Buy | $3.8M (5,700,000 @ $0.66) |
| Jan 30, 2013 | Samuel D Isaly | Director | Buy | $3.8M (5,700,000 @ $0.66) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.